CA2518437C - Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases - Google Patents

Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases Download PDF

Info

Publication number
CA2518437C
CA2518437C CA2518437A CA2518437A CA2518437C CA 2518437 C CA2518437 C CA 2518437C CA 2518437 A CA2518437 A CA 2518437A CA 2518437 A CA2518437 A CA 2518437A CA 2518437 C CA2518437 C CA 2518437C
Authority
CA
Canada
Prior art keywords
group
hydrogen
alkyl
halogen
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2518437A
Other languages
English (en)
French (fr)
Other versions
CA2518437A1 (en
Inventor
James Patrick Dunn
Steven Swallow
Zachary Kevin Sweeney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2518437A1 publication Critical patent/CA2518437A1/en
Application granted granted Critical
Publication of CA2518437C publication Critical patent/CA2518437C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CA2518437A 2003-03-24 2004-03-22 Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases Expired - Lifetime CA2518437C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45713003P 2003-03-24 2003-03-24
US60/457,130 2003-03-24
PCT/EP2004/002995 WO2004085411A1 (en) 2003-03-24 2004-03-22 Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases

Publications (2)

Publication Number Publication Date
CA2518437A1 CA2518437A1 (en) 2004-10-07
CA2518437C true CA2518437C (en) 2012-07-10

Family

ID=33098199

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2518437A Expired - Lifetime CA2518437C (en) 2003-03-24 2004-03-22 Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases

Country Status (20)

Country Link
US (2) US7208509B2 (https=)
EP (1) EP1608633B1 (https=)
JP (1) JP4708329B2 (https=)
KR (1) KR101122456B1 (https=)
CN (1) CN100588650C (https=)
AR (1) AR043673A1 (https=)
AU (1) AU2004224153B2 (https=)
BR (2) BRPI0408767B8 (https=)
CA (1) CA2518437C (https=)
CL (1) CL2004000590A1 (https=)
CO (1) CO5601029A2 (https=)
ES (1) ES2574580T3 (https=)
HR (1) HRP20050830A2 (https=)
IL (1) IL170343A (https=)
MX (1) MXPA05010210A (https=)
NO (1) NO334095B1 (https=)
NZ (1) NZ541829A (https=)
RU (1) RU2342367C2 (https=)
TW (1) TW200505441A (https=)
WO (1) WO2004085411A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011235568B2 (en) * 2010-03-30 2013-09-12 Merck Canada Inc. Non-nucleoside reverse transcriptase inhibitors

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550857A (en) * 2004-04-01 2009-12-24 Aventis Pharma Inc 1,3,4-oxadiazol-2-ones as PPAR delta modulators
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
WO2006010545A1 (en) * 2004-07-27 2006-02-02 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
CN101180280A (zh) * 2005-03-24 2008-05-14 弗·哈夫曼-拉罗切有限公司 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP2009510013A (ja) * 2005-09-30 2009-03-12 エフ．ホフマン−ラ ロシュ アーゲー Ｎｎｒｔ阻害剤
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
ATE545637T1 (de) * 2005-12-15 2012-03-15 Astrazeneca Ab Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
SG183007A1 (en) 2006-07-07 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
CA2658984C (en) * 2006-08-16 2014-12-02 Joshua Kennedy-Smith Non-nucleoside reverse transcriptase inhibitors
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
PL3150586T3 (pl) * 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
MX2009010932A (es) * 2007-04-09 2009-10-29 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
BRPI0811645A2 (pt) 2007-05-30 2014-11-11 Hoffmann La Roche Inibidores de transcriptase reversa de não-nucleosídeo
BRPI0811988B1 (pt) * 2007-05-30 2021-05-25 F. Hoffmann-La Roche Ag Composto intermediário e processo para preparação de triazolonas
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
WO2008157330A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
EP2170836A1 (en) * 2007-06-22 2010-04-07 F. Hoffmann-Roche AG Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors
US8492415B2 (en) * 2007-07-03 2013-07-23 Yale University Azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV)
RU2495878C2 (ru) * 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN104230929B (zh) * 2013-06-19 2015-11-18 华东师范大学 一种非核苷类hiv-1反转录酶抑制剂
WO2015153304A1 (en) 2014-04-01 2015-10-08 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
WO2026042788A1 (ja) * 2024-08-20 2026-02-26 塩野義製薬株式会社 複素環誘導体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274185A (en) 1963-10-08 1966-09-20 S E Massengill Company Phthalazine derivatives
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
JP2593084B2 (ja) 1986-12-19 1997-03-19 メレルダウファーマスーティカルズ インコーポレーテッド ５−アリールー３ｈ−１，２，４−トリアゾールー３−オン類の神経変性障害の処置への用途
PH24094A (en) 1986-12-19 1990-03-05 Merrell Dow Pharma 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
US5436252A (en) 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US4942236A (en) 1987-09-30 1990-07-17 American Home Products Corporation 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as antiallergic and antiinflammatory agents
US5103014A (en) 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4826990A (en) 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4966909A (en) 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
US5331002A (en) 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
PL223343B1 (pl) * 2000-10-30 2016-10-31 Kudos Pharm Ltd Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
JP2002275165A (ja) * 2001-01-12 2002-09-25 Sumitomo Pharmaceut Co Ltd トリアゾール誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011235568B2 (en) * 2010-03-30 2013-09-12 Merck Canada Inc. Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
US7348345B2 (en) 2008-03-25
BRPI0408767B8 (pt) 2021-05-25
JP2006521319A (ja) 2006-09-21
RU2005132632A (ru) 2006-06-10
CO5601029A2 (es) 2006-01-31
NO334095B1 (no) 2013-12-09
AU2004224153A1 (en) 2004-10-07
US7208509B2 (en) 2007-04-24
CA2518437A1 (en) 2004-10-07
JP4708329B2 (ja) 2011-06-22
US20070179157A1 (en) 2007-08-02
AR043673A1 (es) 2005-08-03
CN1759104A (zh) 2006-04-12
CL2004000590A1 (es) 2005-02-04
TW200505441A (en) 2005-02-16
NO20054264D0 (no) 2005-09-15
AU2004224153B2 (en) 2009-04-02
BR122016023941B1 (pt) 2021-10-13
RU2342367C2 (ru) 2008-12-27
BRPI0408767B1 (pt) 2017-10-31
EP1608633B1 (en) 2016-04-20
KR20050115294A (ko) 2005-12-07
EP1608633A1 (en) 2005-12-28
NZ541829A (en) 2008-11-28
NO20054264L (no) 2005-10-14
ES2574580T3 (es) 2016-06-20
HRP20050830A2 (en) 2006-09-30
BRPI0408767A (pt) 2006-03-28
IL170343A (en) 2014-03-31
KR101122456B1 (ko) 2012-04-26
US20040192704A1 (en) 2004-09-30
CN100588650C (zh) 2010-02-10
MXPA05010210A (es) 2005-11-23
WO2004085411A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
CA2518437C (en) Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
JP4485520B2 (ja) 逆転写酵素阻害剤としてのベンジル−ピリダジノン類
US7906540B2 (en) Non-nucleoside reverse transcriptase inhibitors
US7241794B2 (en) Nonnucleoside reverse transcriptase inhibitors
CN1993332B (zh) 作为非核苷逆转录酶抑制剂的苄基三唑酮化合物
CA2600759A1 (en) 1,2,4-triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors
WO2010026075A1 (en) Pyridine derivatives as inhibitors of hiv-i reverse transcriptase
KR100803481B1 (ko) 비-뉴클레오사이드 역전사효소 억제제로서의벤질트라이아졸론 화합물

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20240322